Welcome to the European Journal of Cancer’s Advances in Melanoma Resource Centre. The Resource Centre, edited by Reinhard Dummer, University Hospital, Zurich, will provide you with the latest research on melanoma, including a selection of original research and review articles from some of the world’s leading journals, case studies, and other educational material. New articles will be added to the Resource Centre regularly and are openly available to our readers.
Paper of the Month
Professor Reinhard Dummer, Editor of the Melanoma Resource Centre, has selected the following paper as December Paper of the Month:
Nature Medicine 2013 Jun;19(6):747-52.
Which antigens facilitate tumor rejection during successful immunotherapy
The successful outcome of an immunotherapy is associated with the infiltration of tumor-specific T-killer lymphocytes in the tumor tissue.
These lymphocytes are able to detect various antigens presented in the HLA class I molecules including melanocytic differentiation antigens, cancer/testis antigens and other antigens. Robbins PF and Rosenberg SA and colleagues have developed a new screening approach that allows to find mutated proteins of individual tumor cells. The respective T-cell epitopes were synthesized. The authors have elegantly shown that private mutations in the tumor cells are strong antigens that facilitate tumor rejection by adoptive T-cell transfer.
Professor Dummer is Vice-Chairman of the Department of Dermatology and Head of the Skin Cancer Unit at the University Hospital of Zürich. Professor Dummer graduated in Medicine in 1986.
In 1992 he achieved the Board certification in Dermatology and in 2004 the Board certification in Allergology and Clinical Immunology, as well as the Board certification in Dermatopathology.
Professor Dummer’s main fields of interest are skin cancers, translational research, drug development...
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
G. V. Long, U. Trefzer, M.A. Davies et al.
The Lancet Oncology, Volume 13, Issue 11, Pages 1087 - 1095, November 2012
New Clinical Practice Guidelines from ESMO
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Dummer, A. Hauschild, M. Guggenheim et al.
Annals of Oncology, Volume 23, Supplement 7, vii86-vii91, 2012
EJC Society Partners
About the video
BRAF inhibitors, MEK inhibitors and immunotherapies are transforming the landscape in melanoma treatment. Resource Centre Editor, Reinhard Dummer (University Hospital of Zurich, Switzerland) discusses new trial data presented at ESMO 2012, and explains to Helen Saul, EJC news editor, why the recent advances are important, not just in improving outcomes for patients now, but also in generating the knowledge, the interest and the optimism which are likely to lead to further success in future.